Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data [Yahoo! Finance]
Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Company Research
Source: Yahoo! Finance
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases such as obesity and diabetes. Leveraging AI-powered drug discovery, the company designs and optimizes candidates with greater speed and precision, positioning itself as a leading AI-driven biotech innovator. Structure Therapeutics Inc. (NASDAQ:GPCR)'s lead obesity candidate, aleniglipron (GSBR-1290), is progressing through two Phase 2b studies, ACCESS and ACCESS II, testing doses up to 240 mg to optimize efficacy and competitive positioning. Topline results are expected by year-end 2025, representing a key catalyst for validating its AI-enabled approach in clinical settings. In addition, the company plans to initiate Phase 1 trials for ACCG-2671, an oral amylin receptor agonist, expanding its metabolic disease portfolio with therapies potentially complementary to GLP-1 drugs. Financially, Structure Therapeutics Inc. (NASDAQ:GPCR)
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent HighlightsGlobeNewswire
GPCR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- GPCR's page on the SEC website